Pandemic Perspectives: 20-Plus Vaccines In Development As India Tackles COVID-19 Surge
Will Exports Resume In August?
Executive Summary
From mRNA to subunit vaccines, Indian companies have 20 COVID-19 vaccine candidates, while three have already been approved. An August nod for Biological E could not just cut down time to immunize the country's population but also allow exports to resume.
You may also be interested in...
Lupin Seeks Anti-Obesity Drug Alliances While Aiming For No.2 Spot In Diabetes
In an interview with Scrip, Lupin’s MD Nilesh Gupta spoke about seeking alliances to address the anti-obesity market in India post a demand surge for Wegovy and Mounjaro, the company’s thrust into pharma-adjacent businesses, the limited impact so far of the Israel-Palestine conflict on Indian pharma and more.
Watch Out Pfizer, Moderna - India’s First mRNA Vaccine Is Here
With India’s first and the world’s third mRNA vaccine, Gennova plans to provide access to its COVID-19 vaccine to those deprived of doses from Pfizer and Moderna. HDT Bio Corp’s suit in the US is not seen impacting marketing plans in India, COO tells Scrip
Is India’s Budget Bad News For COVID-19 Boosters, New Vaccines?
India’s 2022-23 budget cuts the outlay for COVID-19 vaccines to a seventh the previous amount. Is that worrying or does it leave the door open for private sales of vaccines? With over 75% of the country's adult population now fully vaccinated, what does it mean for booster shots and yet to be approved SARS-CoV-2 vaccines?